PE20001384A1 - Derivados de acetamida no peptidicos como antagonistas de receptor de nk1 - Google Patents

Derivados de acetamida no peptidicos como antagonistas de receptor de nk1

Info

Publication number
PE20001384A1
PE20001384A1 PE1999001281A PE00128199A PE20001384A1 PE 20001384 A1 PE20001384 A1 PE 20001384A1 PE 1999001281 A PE1999001281 A PE 1999001281A PE 00128199 A PE00128199 A PE 00128199A PE 20001384 A1 PE20001384 A1 PE 20001384A1
Authority
PE
Peru
Prior art keywords
alkyl
peptidic
receptor antagonists
thenyl
propionamide
Prior art date
Application number
PE1999001281A
Other languages
English (en)
Inventor
David Christopher Horwell
Mark Wallace Creswell
Michael Higginbottom
Russell Andrew Lewthwaite
Martyn Clive Pritchard
Jennifer Raphy
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20001384A1 publication Critical patent/PE20001384A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTOS DERIVADOS DE ACETAMIDA NO PEPTIDICOS DE FORMULA I, DONDE R ES PIRIDILO, TIENILO, FURILO, PIRROLILO, PIRAZOLILO, QUINOLINILO, ISOQUINOLILO, NAFTILO, ENTRE OTROS; O R1 Y R2 SON H, ALQUILO C1-C4; m ES 0-3; X ES NHCONH, NR8; R8 ES H, ALQUILO C1-C4; R3 ES H, ALQUILO C1-C4; n ES 1-2; R4 ES NAFTILO, INDOLILO; R9 ES H, ALQUILO C1-C4; R5 Y R7 SON H, (CH2)pR10; p ES 1-3; R10 ES H, CH3, CN, OH, OCH3, CO2CH3, NH2, NHCH3, N(CH3)2; q ES 0-4; R6 ES FENILO, PIRIDILO, TIENILO, FURILO, PIRROLILO, ALQUILO C1-C3, CICLOALQUILO C5-C8, ENTRE OTROS; CUANDO R5 Y R6 ESTAN UNIDOS POR UN ENLACE FORMAN UN ANILLO. SON COMPUESTOS PREFERIDOS 2-[(BENZOFURAN-2-ILMETIL)-AMINO]-3-(1H-INDOL-3-IL)-2-METIL-N-(1-FENIL-ETIL)PROPIONAMIDA, [R-(R*,S*)]; 2-[(BENZOFURAN-2-ILMETIL)AMINO]-3-(1H-INDOL-3-IL)-2-METIL-N-(1-PIRIDIN-4-IL-ETIL)-PROPIONAMIDA, [R-(R*,S*)], ENTRE OTROS. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR NEUROQUININA NK1, POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE UN TRASTORNO DEL SNC, COMO DOLOR, ANSIEDAD, DEPRESION, ESQUIZOFRENIA, NEURALGIA, STRESS, TRASTORNO ALERGICO O INFLAMATORIO
PE1999001281A 1998-12-18 1999-12-17 Derivados de acetamida no peptidicos como antagonistas de receptor de nk1 PE20001384A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11272598P 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
PE20001384A1 true PE20001384A1 (es) 2000-12-30

Family

ID=22345539

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001281A PE20001384A1 (es) 1998-12-18 1999-12-17 Derivados de acetamida no peptidicos como antagonistas de receptor de nk1

Country Status (9)

Country Link
US (2) US6472418B1 (es)
EP (1) EP1140914A1 (es)
JP (1) JP2002533338A (es)
AU (1) AU2180600A (es)
CA (1) CA2355137A1 (es)
CO (1) CO5170508A1 (es)
PE (1) PE20001384A1 (es)
UY (1) UY25864A1 (es)
WO (1) WO2000037462A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399584A1 (en) * 1999-12-22 2001-06-28 Warner-Lambert Company Non peptide tachykinin receptor antagonists
EP1333829A1 (en) * 2000-11-17 2003-08-13 Warner-Lambert Company LLC Treatment of sexual dysfunction using bombesin antagonists
GB2369118A (en) * 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
HUP0301892A3 (en) * 2000-11-17 2005-06-28 Warner Lambert Company Llc Mor Pharmaceutical compositions for treatment of sexual dysfunction and their preparation
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
WO2006101454A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Benzothiophene derivatives: preparation and pharmaceutical applications
EP2594318B1 (en) * 2005-04-15 2020-06-10 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
CN104761515B (zh) 2009-11-12 2018-03-09 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US20150259278A1 (en) 2012-09-27 2015-09-17 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US20200399219A1 (en) * 2017-08-21 2020-12-24 Plex Pharmaceuticals, Inc. Dual acting fkbp12 and fkbp52 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
EP1000930A3 (en) * 1992-08-13 2003-10-29 Warner-Lambert Company Tachykinin antagonists
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
AU693898B2 (en) * 1994-06-06 1998-07-09 Warner-Lambert Company Tachykinin (NK1) receptor antagonists
TR199900364T2 (xx) 1996-08-22 1999-05-21 Warner-Lambert Company Peptid olmayan bombesin resept�r antagonistleri.
WO1999052903A1 (en) * 1998-04-15 1999-10-21 Warner-Lambert Company Prodrugs of benzofuranylmethyl carbamate nk1 antagonists

Also Published As

Publication number Publication date
US20030065007A1 (en) 2003-04-03
CO5170508A1 (es) 2002-06-27
WO2000037462A1 (en) 2000-06-29
JP2002533338A (ja) 2002-10-08
UY25864A1 (es) 2001-08-27
EP1140914A1 (en) 2001-10-10
US6472418B1 (en) 2002-10-29
AU2180600A (en) 2000-07-12
CA2355137A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
BR1100680A (pt) Antagonistas tricìclos de receptores de 5-ht3
ES2141174T3 (es) 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina.
PE106499A1 (es) Antagonistas del receptor ccr-3
ATE512955T1 (de) Stickstoffhaltige heterozyklische derivate und medikamente die diese enthalten
PE20001384A1 (es) Derivados de acetamida no peptidicos como antagonistas de receptor de nk1
LV11035A (lv) Jauni benzimidazolin-2-okso-1-karbonskabes atvasinajumi kuri pielietojami ka serotonina (5-HT) receptoru antagonisti
PE20011035A1 (es) Ureas ciclicas sustituidas como antagonistas de los receptores de neuroquinina
FR2673427B1 (fr) Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
ATE224392T1 (de) Kondensierte tropanderivate als neurotransmitter- reuptake-inhibitoren
ATE128463T1 (de) Piperidin und pyrrolidin derivate.
DK1054885T3 (da) Benzisoxasolderivater med D4-antagonistisk virkning
KR950702978A (ko) 아미드 유도체(Amide derivatives)
PE51499A1 (es) Derivados de 5-aroilnaftaleno
TR22719A (tr) Yeni n-alkil(en)-n-(o,o-disuebstuee-tiofos foril)-n',n'-disuebstituee glisin amidler bunlari hazirlamaya mahsus usuel ve etkili terkip maddesi olarak bu bilesikleri ihtiva eden akarisid ensektisid ve fungisid
HUP0204278A2 (hu) Nem peptid szubsztituált benzotiazepinszármazékok, mint vazopresszin antagonisták, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ECSP993274A (es) Antagonistas de receptor de nk1
ES8403899A1 (es) Un procedimiento para la preparacion de nuevos derivados de benzamida.

Legal Events

Date Code Title Description
FC Refusal